BeiGene, Ltd. (BGNE)
NASDAQ: BGNE · IEX Real-Time Price · USD
162.54
-0.73 (-0.45%)
Jul 26, 2024, 4:00 PM EDT - Market closed
BeiGene Revenue
BeiGene had revenue of $5.36B in the quarter ending March 31, 2024, with 1,096.81% growth. This brings the company's revenue in the last twelve months to $20.05B, up 1,187.43% year-over-year. In the year 2023, BeiGene had annual revenue of $2.46B with 73.65% growth.
Revenue (ttm)
$20.05B
Revenue Growth
+1,187.43%
P/S Ratio
6.17
Revenue / Employee
$260,625
Employees
10,600
Market Cap
16.92B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Baxter International | 14.89B |
| Labcorp Holdings | 12.30B |
| Quest Diagnostics | 9.35B |
| Hologic | 3.96B |
| Align Technology | 3.92B |
| Incyte | 3.77B |
| The Cooper Companies | 3.73B |
| Genmab | 2.57B |
BGNE News
- 3 days ago - MarketVector Indexes Licenses its flagship Ethereum Benchmark Rate to VanEck for ETHV, the pioneering Spot Ethereum ETF - Business Wire
- 3 days ago - BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World - Business Wire
- 8 days ago - BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer - Business Wire
- 6 weeks ago - BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024 - Business Wire
- 6 weeks ago - BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region - Business Wire
- 7 weeks ago - BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference - Business Wire
- 2 months ago - BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL - Business Wire
- 2 months ago - BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024 - Business Wire